Tumor reductive therapies and antitumor immunity

Tumor reductive therapies and antitumor immunity

Tumor reductive therapy is to reduce tumor burden through direct killing of tumor cells. So far, there is no report on the connection between antitumor immunity and tumor reductive therapies. In the last few years, a new category of cancer treatment, immunotherapy, emerged and they are categorized separately from classic cytotoxic treatments (chemo and radiation therapy). The most prominent exa...

Antitumor immunity elicited by tumor cells

Nutrition and tumor immunity: divergent effects of antitumor antibody.

Nutritional deficiency reduces antibody synthetic capacity. Antibody directed against tumor antigens, however, may serve either to heighten tumor immunity, as in antibody-dependent cellular cytotoxicity, or to diminish host resistance to cancer growth by "blocking" cell-mediated tumor immunity. Diets made deficient in specific amino acids are inimical to tumor growth, apparently through reducti...

Catechins and antitumor immunity

Numerous laboratory and clinical studies have reported that the green tea catechin extract Polyphenon E exert anticancer activity, but the underlying mechanism of action was elusive. We have recently shown that Polyphenon E exerts antineoplastic effects by antagonizing tumor-induced myeloid derived suppressor cells (MDSCs).

Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.

PURPOSE Early clinical trials are under way exploring the direct oncolytic potential of reovirus. This study addresses whether tumor infection by reovirus is also able to generate bystander, adaptive antitumor immunity. EXPERIMENTAL DESIGN Reovirus was delivered intravenously to C57BL/6 mice bearing lymph node metastases from the murine melanoma, B16-tk, with assessment of nodal metastatic cl...